A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis Post author: Post published:October 20, 2026 Post category: Continue ReadingA Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis
SRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma Post author: Post published:October 20, 2026 Post category: Continue ReadingSRN-101 AAV Immuno-Gene Therapy for High-Grade Glioma
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome Post author: Post published:October 20, 2026 Post category: Continue ReadingPhase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome
Phase I/II Clinical Trial for CMT4J Post author: Post published:October 20, 2026 Post category: Continue ReadingPhase I/II Clinical Trial for CMT4J
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) Post author: Post published:October 20, 2026 Post category: Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy Post author: Post published:October 20, 2026 Post category: Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy
The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program Post author: Post published:October 20, 2026 Post category: Continue ReadingThe UCLA Delayed Immunological Tolerance after Kidney Transplantation Program
RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration Post author: Post published:October 20, 2026 Post category: Continue ReadingRPESC-RPE-4W Therapy for dry Age-related Macular Degeneration
A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus Post author: Post published:October 20, 2026 Post category: Continue ReadingA phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A Post author: Post published:October 20, 2026 Post category: Continue ReadingPersonalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A
